Background: Incorporating patient preference (PP) information into decision-making has become increasingly important to many stakeholders. However, there is little guidance on which patient preference assessment methods, including preference exploration (qualitative) and elicitation (quantitative) methods, are most suitable for decision-making at different stages in the medical product lifecycle (MPLC). This study aimed to use an empirical approach to assess which attributes of PP assessment methods are most important, and to identify which methods are most suitable, for decisio
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Background: Patient preference (PP)information is not effectively integrated in decision-making thro...
Two key uses of patient preference information are to inform the choice of patient-relevant endpoint...
BACKGROUND: Incorporating patient preference (PP) information into decision-making has become increa...
Patient preferences are critical for the successful development, regulation, and reimbursement of me...
The role of patient preferences is becoming progressively more important throughout the medical prod...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Preference studies are becoming increasingly important within the medical product decision-making co...
Background Patient preferences (PP), which are investigated in PP studies using qualitative or quant...
Background: Patient preferences (PP), which are investigated in PP studies using qualitative or quan...
Introduction: Preference elicitation methods help to increase patient-centred medical decision makin...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should ...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Background: Patient preference (PP)information is not effectively integrated in decision-making thro...
Two key uses of patient preference information are to inform the choice of patient-relevant endpoint...
BACKGROUND: Incorporating patient preference (PP) information into decision-making has become increa...
Patient preferences are critical for the successful development, regulation, and reimbursement of me...
The role of patient preferences is becoming progressively more important throughout the medical prod...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Preference studies are becoming increasingly important within the medical product decision-making co...
Background Patient preferences (PP), which are investigated in PP studies using qualitative or quant...
Background: Patient preferences (PP), which are investigated in PP studies using qualitative or quan...
Introduction: Preference elicitation methods help to increase patient-centred medical decision makin...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should ...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Background: Patient preference (PP)information is not effectively integrated in decision-making thro...
Two key uses of patient preference information are to inform the choice of patient-relevant endpoint...